Plasma homocysteine, vitamin B12 and folate levels in age-related macular degeneration.

Department of Ophthalmology, Hacettepe University Hospital, 06100, Sihhiye, Ankara, Turkey.
Albrecht von Graæes Archiv für Ophthalmologie (Impact Factor: 2.33). 06/2006; 244(5):565-9. DOI: 10.1007/s00417-005-0108-2
Source: PubMed

ABSTRACT The purpose of this study was to investigate the association of age-related macular degeneration (AMD) with plasma homocysteine, vitamin B12, and folate levels.
Sixty patients diagnosed with AMD at our clinic between March 2004 and September 2004 were assessed in a prospective cross-sectional study. Plasma homocysteine, vitamin B12, and folate levels taken after 8 h of fasting from 30 patients with exudative AMD and 30 patients with dry AMD were compared with the results of 30 age- and sex-matched healthy participants.
Patients with both exudative and dry types of AMD had significantly higher plasma homocysteine levels (mean 14.19+/-3.11 micromol/l; 13.07+/-2.90 micromol/l respectively) compared with the controls (mean 10.79+/-2.56 micromol/l; (p=0.000 and p=0.008 respectively). Homocysteine levels were higher in the exudative AMD group compared with the dry AMD group, but the difference was not statistically significant (p=0.290). Plasma vitamin B12 levels were found to be significantly lower in the exudative AMD group (289.14+/-113.44 pg/l) compared with the controls (436.17+/-204.12 pg/l) and dry AMD group (443.47+/-190.83 pg/l; (p=0.000). Plasma folate levels were comparable among groups (p=0.106).
This study suggests an association between elevated plasma homocysteine and AMD regardless of the subtype. Further controlled prospective studies are needed to investigate the possible role of homocysteine in AMD and the effect of vitamin B12 and folate supplementation in this process.

Download full-text


Available from: Koray Gumus, Aug 14, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently, a novel enzymatic method was developed for determination of homocysteine. This method utilizes the electrochemical hydrogen sulfide sensor along with methionine ,-lyase to accomplish the fast, accurate, sensitive and selective measurements. As a continuation of this work, another enzyme, homocysteine ,-lyase, was used and the parallel experiments of using both enzymes were carried out against the effect of pH, sensitivity, linearity, and interferences, in an intended comparison between these two enzymes. The excellent linearity of amperometric currents against homocysteine concentrations, high sensitivities and low detection limits for both enzymes reconfirmed that the electrochemical method is superior over other analytical means. The high enzymatic activity of methionine ,-lyase surpassing homocysteine ,-lyase endowed the former higher sensitivity, lower detection limit and faster response than the latter, suggesting methionine ,-lyase a better candidate for homocysteine measurement by electrochemical method. The differences between these two enzymes on the trends of response time and sensitivity at different pH environments, reactivity toward several forms of homocysteine as well as on the interference from several agents were also addressed and discussed.
    Electroanalysis 05/2007; 19(10):1075 - 1083. DOI:10.1002/elan.200603824 · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine the relationship between circulating inflammatory markers, hemostatic factors, and age-related maculopathy (ARM). A population-based, cross-sectional case-control study drawn from the Blue Mountains Eye Study included 159 early and 38 late ARM cases, and 433 controls matched for age, gender, and smoking. ARM lesions were assessed from retinal photographs according to the Wisconsin ARM grading system. Circulating inflammatory markers (high-sensitivity C-reactive protein [hsCRP], intercellular adhesion molecule [ICAM]-1, and interleukin [IL]-6), white cell count (WCC), and hemostatic factors (fibrinogen, homocysteine, plasminogen activator inhibitor [PAI]-1 and von Willebrand factor [vWF]) were assessed. Age, gender, current smoking, body mass index, hypertension, history of stroke, and cardiovascular events were adjusted for. Adjusted mean levels of each marker were compared between persons with early ARM, those with late ARM, and control subjects, and are presented as probabilities. Adjusted associations with ARM were examined continuously (per SD), and are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Summarizing z scores for inflammation and hemostatic dysfunction were calculated. Increased PAI-1 level was associated with both early (OR 1.2, 95% CI 1.0-1.4 per SD increase) and late ARM (OR 1.3, 95% CI 0.9-1.9 per SD increase). Elevated ICAM-1 level was marginally associated with late ARM (OR 1.3, 95% CI 1.0-1.7 per SD increase). No other significant associations were found between the remaining inflammatory or hemostatic markers and either early or late ARM. Summarized z scores for inflammatory or hemostatic markers also did not suggest any associations. There was no consistent pattern of association found between ARM and circulating inflammatory markers or hemostatic factors in this population-based case-control study.
    Investigative Ophthalmology &amp Visual Science 06/2007; 48(5):1983-8. DOI:10.1167/iovs.06-0223 · 3.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in the USA. Although the treatment of AMD has evolved to include laser photocoagulation, photodynamic therapy, surgical macular translocation and antiangiogenesis agents, treatment options for advanced AMD are limited. Furthermore, the dry form of AMD, albeit less devastating than the wet form, has even fewer viable treatment options. This review summarizes the various biomarkers of AMD and analyzes whether or not they may one day be exploited to determine risks of disease onset, measure progression of disease or even assess the effects of treatment of AMD. Potential biomarkers are important to identify since some might be utilized to reflect the disease state of a particular patient and to individualize therapy. Although studies have yielded promising results for nutrient and inflammatory biomarkers, these results have been inconsistent. At present, the best available markers of AMD risk are single nucleotide polymorphisms (SNPs). SNPs in complement factor H (CFH) and PLEKHA1/ARMS2/HtrA1 capture a substantial fraction of AMD risk and permit the identification of individuals at high risk of developing AMD.
    Expert Review of Ophthalmology 07/2007; 2(3):443-457. DOI:10.1586/17469899.2.3.443